亿帆医药(002019) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit for the first half of 2024 is projected to be between 24,600,000 and 28,000,000 CNY, representing a year-on-year increase of 126.39% to 157.68% compared to 10,866,040 CNY in the same period last year[4]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 17,506,830 and 19,631,830 CNY, reflecting a growth of 85.86% to 108.42% from 9,419,440 CNY in the previous year[4]. - The basic earnings per share are anticipated to be between 0.20 CNY and 0.23 CNY, compared to 0.09 CNY per share in the same period last year[4]. Factors Contributing to Profit Growth - The significant increase in net profit is attributed to the initial market deployment of new and existing proprietary pharmaceutical products, leading to a higher growth rate in sales gross profit compared to expense growth[7]. - The company has also received increased government subsidies related to revenue, contributing to the profit growth[7]. Financial Reporting - The financial data presented is preliminary and has not yet been audited by an accounting firm, with final figures to be disclosed in the company's 2024 semi-annual report[10].